Ferrostatin-1 alleviates lipopolysaccharide-induced cardiac dysfunction

Area of Science:

• Cardiovascular Biology
• Inflammation Research
• Cell Death Mechanisms

Background:

• Sepsis frequently causes cardiac dysfunction due to severe inflammatory responses.
• Ferroptosis, a form of regulated cell death, is implicated in sepsis-induced cardiac inflammation.

Purpose of the Study:

• To investigate the potential of ferrostatin-1 (Fer-1), a ferroptosis inhibitor, in ameliorating sepsis-induced cardiac dysfunction.
• To elucidate the underlying molecular mechanisms, including the role of ferroptosis and inflammatory pathways.

Main Methods:

• A rat model of sepsis-induced cardiac dysfunction was established using lipopolysaccharide (LPS) injection.
• Cardiac function was assessed via echocardiography, histopathology, and biochemical analysis.
• Western blot analysis was used to evaluate protein expression related to ferroptosis, inflammation, and signaling pathways.

Main Results:

• LPS injection led to impaired cardiac systolic function, elevated cardiac injury and ferroptosis markers (PTGS2), increased myocardial iron deposition, and altered expression of iron-related proteins (FPN, TfR, FTL, FTH1).
• LPS challenge also increased lipid peroxidation (decreased GPX4), inflammatory cytokine levels (TNF-α, IL-1β, IL-6), and inflammatory cell infiltration.
• Fer-1 treatment reversed most LPS-induced adverse effects, except for TfR expression, and significantly reduced TLR4, phospho-NF-κB, and phospho-IκBα levels.

Conclusions:

• Ferrostatin-1 effectively improves sepsis-induced cardiac dysfunction in rats.
• The protective effects of Fer-1 are, at least partially, mediated through the inhibition of the TLR4/NF-κB signaling pathway.
• Targeting ferroptosis presents a potential therapeutic strategy for sepsis-related cardiac complications.